Chemokine-like factor 1: A promising therapeutic target in human diseases

Dissecting the role of the CXCL12/CXCR4 axis in acute myeloid leukaemia

(2020) Eleni E Ladikou et al.   BRITISH JOURNAL OF HAEMATOLOGY

CKLF1 Enhances Inflammation-mediated Carcinogenesis and Prevents Doxorubicin-induced Apoptosis via IL-6/STAT3 Signaling in HCC

(2019) Fan Zhu et al.   CLINICAL CANCER RESEARCH

CKLF1 Aggravates Focal Cerebral Ischemia Injury at Early Stage Partly by Modulating Microglia/Macrophage Toward M1 Polarization Through CCR4

(2019) Chen Chen et al.   CELLULAR AND MOLECULAR NEUROBIOLOGY

Emerging PEGylated non-biologic drugs

(2019) Eun Ji Park et al.   EXPERT OPINION ON EMERGING DRUGS

Olaptesed pegol (NOX-A12) with bendamustine and rituximab: a phase IIa study in patients with relapsed/refractory chronic lymphocytic leukemia

(2019) Michael Steurer et al.   HAEMATOLOGICA

IMM-H004 Protects against Cerebral Ischemia Injury and Cardiopulmonary Complications via CKLF1 Mediated Inflammation Pathway in Adult and Aged Rats

(2019) Qidi Ai et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis

(2019) Zefang Tang et al.   NUCLEIC ACIDS RESEARCH

CKLF1 aggravates neointimal hyperplasia by inhibiting apoptosis of vascular smooth muscle cells through PI3K/AKT/NF-κB signaling

(2019) Yanyu Duan et al.   BIOMEDICINE & PHARMACOTHERAPY

A Phase Ib/II Trial of the First-in-Class Anti-CXCR4 Antibody Ulocuplumab in Combination with Lenalidomide or Bortezomib Plus Dexamethasone in Relapsed Multiple Myeloma

(2019) Irene M. Ghobrial et al.   CLINICAL CANCER RESEARCH

A phase I–II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia

(2018) David Martínez-Cuadrón et al.   ANNALS OF HEMATOLOGY

Progress in pharmacological research of chemokine like factor 1 (CKLF1)

(2018) Dan-Dan Liu et al.   CYTOKINE

Phase I trial of plerixafor combined with decitabine in newly diagnosed older patients with acute myeloid leukemia

(2018) Gail J Roboz et al.   HAEMATOLOGICA

Phase I trial of plerixafor combined with decitabine in newly diagnosed older patients with acute myeloid leukemia

(2018) Gail J Roboz et al.   HAEMATOLOGICA

Olaptesed pegol, an anti-CXCL12/SDF-1 Spiegelmer, alone and with bortezomib–dexamethasone in relapsed/refractory multiple myeloma: a Phase IIa Study

(2017) H Ludwig et al.   LEUKEMIA

A new antagonist for CCR4 attenuates allergic lung inflammation in a mouse model of asthma

(2017) Yang Zhang et al.   Scientific Reports

Role of chemokine pathways in hepatobiliary cancer

(2016) Josef Ehling et al.   CANCER LETTERS

Regulatory T cells in cancer immunotherapy

(2016) Atsushi Tanaka et al.   CELL RESEARCH

Cancer stem cells

(2016) Jeremy N. Rich   MEDICINE

Inhibition of chemokine-like factor 1 improves blood-brain barrier dysfunction in rats following focal cerebral ischemia

(2016) Ling-Lei Kong et al.   NEUROSCIENCE LETTERS

Study of the functional mechanisms of osteopontin and chemokine-like factor 1 in the development and progression of abdominal aortic aneurysms in rats

(2016) Jun Li et al.   Experimental and Therapeutic Medicine

Targeting the CCL2-CCR2 signaling axis in cancer metastasis

(2016) Su Yin Lim et al.   Oncotarget

Cytokine amplification and macrophage effector functions in aortic inflammation and abdominal aortic aneurysm formation

(2016) Talha Ijaz et al.   Journal of Thoracic Disease

Targeting chemokine receptors in disease – a case study of CCR4

(2015) Roberto Solari et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Chemokine-Like Factor 1-Derived C-Terminal Peptides Induce the Proliferation of Dermal Microvascular Endothelial Cells in Psoriasis

(2015) Yaqi Tan et al.   PLoS One

The effect of CCR2 inhibitor CCX140-B on residual albuminuria in patients with type 2 diabetes and nephropathy: a randomised trial

(2015) Dick de Zeeuw et al.   Lancet Diabetes & Endocrinology

Cytokines and chemokines: At the crossroads of cell signalling and inflammatory disease

(2014) Mark D. Turner et al.   BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR CELL RESEARCH

The chemokine-like factor 1 induces asthmatic pathological change by activating nuclear factor-κB signaling pathway

(2014) Gang Li et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Neutralization of chemokine-like factor 1, a novel C-C chemokine, protects against focal cerebral ischemia by inhibiting neutrophil infiltration via MAPK pathways in rats

(2014) Ling Kong et al.   Journal of Neuroinflammation

Inhibition of chemokine-like factor 1 protects against focal cerebral ischemia through the promotion of energy metabolism and anti-apoptotic effect

(2014) Ling Lei Kong et al.   NEUROCHEMISTRY INTERNATIONAL

Chemokine-like factor 1 promotes the migration of rat primary cortical neurons by the induction of actin polymerization

(2014) Zhen-Zhen Wang et al.   NEUROREPORT

Effects of chemokine-like factor 1 on vascular smooth muscle cell migration and proliferation in vascular inflammation

(2012) Tao Zhang et al.   ATHEROSCLEROSIS

Antagonistic effect of C19 on migration of vascular smooth muscle cells and intimal hyperplasia induced by chemokine-like factor 1

(2012) Tao Zhang et al.   MOLECULAR BIOLOGY REPORTS

Design and Synthesis of a Series of Pyrido[2,3-d]pyrimidine Derivatives as CCR4 Antagonists

(2012) Hongwei Gong et al.   MOLECULES

JAK/STAT signaling in hematological malignancies

(2012) W Vainchenker et al.   ONCOGENE

Effect of CC Chemokine Receptor 2 CCR2 Blockade on Serum C-Reactive Protein in Individuals at Atherosclerotic Risk and With a Single Nucleotide Polymorphism of the Monocyte Chemoattractant Protein-1 Promoter Region

(2011) Jim Gilbert et al.   AMERICAN JOURNAL OF CARDIOLOGY

Roles of the PI3K/Akt pathway and autophagy in TLR3 signaling-induced apoptosis and growth arrest of human prostate cancer cells

(2011) Nanae Harashima et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

IL-6 signaling in autoimmunity, chronic inflammation and inflammation-associated cancer

(2011) Markus F. Neurath et al.   CYTOKINE & GROWTH FACTOR REVIEWS

Alleviation of murine allergic rhinitis by C19, a C-terminal peptide of chemokine-like factor 1 (CKLF1)

(2011) Yi Zheng et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

XCL1 and XCR1 in the immune system

(2011) Yu Lei et al.   MICROBES AND INFECTION

Expression of chemokine-like factor 1 after focal cerebral ischemia in the rat

(2011) Ling-Lei Kong et al.   NEUROSCIENCE LETTERS

C19, a C-terminal peptide of chemokine-like factor 1, protects the brain against focal brain ischemia in rats

(2011) Ling-Lei Kong et al.   NEUROSCIENCE LETTERS

The CKLF1-C19 peptide attenuates allergic lung inflammation by inhibiting CCR3- and CCR4-mediated chemotaxis in a mouse model of asthma

(2010) L. Tian et al.   ALLERGY

Discovery and Optimization of Novel 3-Piperazinylcoumarin Antagonist of Chemokine-like Factor 1 with Oral Antiasthma Activity in Mice

(2010) Gang Li et al.   JOURNAL OF MEDICINAL CHEMISTRY

CMTM3, Located at the Critical Tumor Suppressor Locus 16q22.1, Is Silenced by CpG Methylation in Carcinomas and Inhibits Tumor Cell Growth through Inducing Apoptosis

(2009) Y. Wang et al.   CANCER RESEARCH

Prediction of Recurrence-Free Survival in Postoperative Non-Small Cell Lung Cancer Patients by Using an Integrated Model of Clinical Information and Gene Expression

(2008) E.-S. Lee et al.   CLINICAL CANCER RESEARCH

Analysis of the interactions between the peptides from secreted human CKLF1 and heparin using capillary zone electrophoresis

(2008) Yi Liu et al.   JOURNAL OF PEPTIDE SCIENCE

Two C-terminal peptides of human CKLF1 interact with the chemokine receptor CCR4

(2007) Ying Wang et al.   INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY